Replies to post #38915 on Biotech Values

[dewophile]

good point..and there is certainly still room for improvement in the 25% or so non-gen-1 population despite the better overall response of these genotypes to current soc
from what I recall vx-950 doesn't bind all that well to non-gen-1 proteases so i don't think we'll see trials in other genotypes any time soon